GlassScriptPhysician profile
Susan J Appel
NPI 1770816050
$5,573.91
in general payments reported to CMS, 2019-2025
26 companies · $663 in 2025
The $663 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,093 · 2022: $1,270 · 2023: $1,370 · 2024: $1,178 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,211.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $802.13 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals LP | $559.37 | 2021-2023 | Tezspire |
| Abbvie INC. | $553.71 | 2021-2023 | |
| Novo Nordisk INC | $538.45 | 2021-2023 | Wegovy |
| Axsome Therapeutics, INC. | $386.10 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $256.54 | 2022 | |
| Amgen INC. | $233.33 | 2023-2024 | Repatha |
| Scpharmaceuticals INC. | $220.45 | 2023-2024 | |
| Abbott Laboratories | $140.10 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Alexion Pharmaceuticals, INC. | $128.56 | 2023 | |
| Sumitomo Pharma America, INC. | $125.40 | 2024 | Myfembree |
| Esperion Therapeutics, INC. | $125.00 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $124.34 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $121.84 | 2024 | Evkeeza |
| Eisai INC. | $121.45 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $120.12 | 2024 | Zepbound |
| Edwards Lifesciences Corporation | $119.01 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ultragenyx Pharmaceutical INC. | $116.28 | 2022 | |
| Merck Sharp & Dohme LLC | $114.05 | 2023 | Verquvo |
| Mannkind Corporation | $108.67 | 2022 | |
| Corcept Therapeutics | $99.04 | 2023 | Korlym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $97.73 | 2025 | |
| Idorsia Pharmaceuticals US INC | $96.40 | 2025 | Tryvio |
| Bayer Healthcare Pharmaceuticals INC. | $95.31 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $86.02 | 2025 | |
| Alnylam Pharmaceuticals INC. | $84.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Appel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.